X4 Pharmaceuticals, Inc. (XFOR)
NasdaqCM · USD · Healthcare · Biotechnology
$3.25 (+0.31%) as of
Key statistics
- Market cap
- 322.23M
- P/E (TTM)
- 162.50
- Forward P/E
- -4.23
- EPS (TTM)
- 0.0200
- Dividend yield
- 0.00%
- 52-week range
- 2.4300 – 4.8300
- Beta
- 0.46
- Revenue (TTM)
- 15.85M
- Profit margin
- 0.00%
- Analyst target
- $11.60
- Volume
- 701.65k
About X4 Pharmaceuticals, Inc.
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Boston, MA, United States
- Employees
- 45
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.